FDA approves once-weekly hemophilia A therapy 27-Feb-2023 By Rachel Arthur The US Food and Drug Administration (FDA) has approved Sanofi and Sobi’s Altuviiio (efanesoctocog alfa): a first-in-class, high-sustained factor VIII replacement therapy.
US FDA approves first HLH treatment in 24 years 23-Nov-2018 By Maggie Lynch Sobi’s Gamifant is approved as a treatment for pediatric and adult patients with primary hemophagocytic lymphohistiocytosis.
